Obexelimab Cuts Steroid Toxicity in IgG4 Disease

A 52-week randomized trial found obexelimab reduced glucocorticoid-related toxicity compared with placebo in patients with IgG4-related disease.

Updated on Nov. 9, 2026 in Allergies

Bold flat-color editorial illustration of a plain amber injection pen beside a glass vial on a cream surface, against a solid red field.
Obexelimab, given as a weekly injection for 52 weeks, reduced glucocorticoid-related toxicity compared with placebo in patients with IgG4-related disease, a randomized trial found. AI Illustration. Upload story photo >

In a 52-week randomized trial, subcutaneous obexelimab 250 mg weekly outperformed placebo in reducing glucocorticoid toxicity in IgG4-related disease patients. Obexelimab also reduced disease flares and glucocorticoid exposure compared with placebo.

Why it matters

Glucocorticoids work in IgG4-related disease, but relapses are common once they are tapered and repeated courses cause substantial toxicity. An effective steroid-sparing option could reduce that burden for patients worldwide.

The randomized trial reported GTI-CWS scores of 28.2 for obexelimab and 39.6 for placebo at 52 weeks, a difference of 11.4. At week 52, 29% of obexelimab patients had a 30-point GTI worsening versus 49% on placebo, and the study does not report results beyond 52 weeks.

The players

Obexelimab

An investigational monoclonal antibody being tested as a steroid-sparing treatment for IgG4-related disease.

Matthew C. Baker

A Stanford University researcher who is the lead author of the obexelimab study.

The details

Patients were randomly assigned to weekly subcutaneous obexelimab 250 mg or placebo for 52 weeks after glucocorticoid induction and a taper to discontinuation at week 8. Obexelimab reduced infection, glucocorticoid myopathy and neuropsychiatric toxicity compared with placebo, while skin toxicity was comparable and hyperlipidemia rose by one point in the obexelimab group.

Timeline

  1. Week 8: glucocorticoid taper reaches discontinuation in the trial.

  2. Week 24: interim GTI-CWS comparison favors obexelimab over placebo.

  3. Week 52: final GTI-CWS and toxicity thresholds measured in both arms.

Roadmap

Glucocorticoids have long been the mainstay for IgG4-related disease, but repeated courses bring substantial toxicity and frequent relapse. The obexelimab trial tests whether a steroid-sparing biologic can shift that trade-off in patients.

For patients with IgG4-related disease, a steroid-sparing option could reduce repeated glucocorticoid exposure and its side effects, including infection and myopathy. Trial results so far relate to research use and do not change current prescribing.

The takeaway

Patients and clinicians managing IgG4-related disease should weigh the trade-off between steroid-related toxicity and relapse risk when planning treatment. Steroid-sparing options like obexelimab are still investigational and should be discussed with a specialist.

Further reading

Explore more on Allergies for context on immune-mediated conditions treated with biologic therapies.

Source note: This article includes information reported by Healio.